ACE and congenital heart disease: Consistent with our study, a systematic review on the effects of ACE inhibitors, Ang II receptor blockers, and aldosterone antagonists in adults with congenital heart disease and RV dysfunction found that RAS inhibition did not have a beneficial effect in these patients, suggesting a lack of association between RAS peptides and RV function.